Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2020 Publisher: Baxter Healthcare Ltd., Caxton Way, Thetford, Norfolk, IP24 3SE, United Kingdom
Onkotrone Injection.
2 mg/ml concentrate for solution for infusion.
| Pharmaceutical Form |
|---|
|
Concentrate for solution for infusion. Sterile dark blue aqueous solution. |
Each 1 ml of solution contains 2 mg mitoxantrone (as hydrochloride).
| Active Ingredient | Description | |
|---|---|---|
| Mitoxantrone |
Mitoxantrone, a DNA-reactive agent that intercalates into deoxyribonucleic acid (DNA) through hydrogen bonding, causes crosslinks and strand breaks. Mitoxantrone also interferes with ribonucleic acid (RNA) and is a potent inhibitor of topoisomerase II, an enzyme responsible for uncoiling and repairing damaged DNA. |
| List of Excipients |
|---|
|
Sodium chloride |
Containers:
Clear glass type 1 injection vial with rubber stopper and aluminium flange cap.
Contents:
Onkotrone Injection is a sterile dark blue aqueous solution of mitoxantrone hydrochloride equivalent to 2 mg/ml. It is available in the following vial sizes:
Baxter Healthcare Ltd., Caxton Way, Thetford, Norfolk, IP24 3SE, United Kingdom
PL 00116/0398
Date of first authorisation: 14 September 2004
Date of last renewal: 16 September 2010
| Drug | Countries | |
|---|---|---|
| ONKOTRONE | Australia, Estonia, Lithuania, Malta, New Zealand, Romania, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
